| Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily, V Baldo, ... The Lancet 394 (10197), 497-509, 2019 | 1029 | 2019 |
| Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis M Drolet, É Bénard, MC Boily, H Ali, L Baandrup, H Bauer, S Beddows, ... The Lancet infectious diseases 15 (5), 565-580, 2015 | 899 | 2015 |
| Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study JML Brotherton, M Fridman, CL May, G Chappell, AM Saville, DM Gertig The Lancet 377 (9783), 2085-2092, 2011 | 673 | 2011 |
| The projected timeframe until cervical cancer elimination in Australia: a modelling study MT Hall, KT Simms, JB Lew, MA Smith, JML Brotherton, M Saville, ... The Lancet Public Health 4 (1), e19-e27, 2019 | 463 | 2019 |
| Human papillomavirus vaccine introduction–the first five years LE Markowitz, V Tsu, SL Deeks, H Cubie, SA Wang, AS Vicari, ... Vaccine 30, F139-F148, 2012 | 436 | 2012 |
| Fall in human papillomavirus prevalence following a national vaccination program SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, E Cummins, B Liu, ... The Journal of infectious diseases 206 (11), 1645-1651, 2012 | 374 | 2012 |
| Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study DM Gertig, JML Brotherton, AC Budd, K Drennan, G Chappell, AM Saville BMC medicine 11, 1-12, 2013 | 369 | 2013 |
| Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study SN Tabrizi, JML Brotherton, JM Kaldor, SR Skinner, B Liu, D Bateson, ... The Lancet infectious diseases 14 (10), 958-966, 2014 | 366 | 2014 |
| The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? C Patel, JML Brotherton, A Pillsbury, S Jayasinghe, B Donovan, ... Eurosurveillance 23 (41), 1700737, 2018 | 351 | 2018 |
| EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease M Arbyn, S De Sanjosé, M Saraiya, M Sideri, J Palefsky, C Lacey, ... International journal of cancer 131 (9), 1969-1982, 2012 | 343 | 2012 |
| Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme … E Crowe, N Pandeya, JML Brotherton, AJ Dobson, S Kisely, SB Lambert, ... Bmj 348, 2014 | 315 | 2014 |
| The IARC perspective on cervical cancer screening V Bouvard, N Wentzensen, A Mackie, J Berkhof, J Brotherton, ... New England Journal of Medicine 385 (20), 1908-1918, 2021 | 258 | 2021 |
| Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers JS Hocking, A Stein, EL Conway, D Regan, A Grulich, M Law, ... British journal of cancer 104 (5), 886-891, 2011 | 242 | 2011 |
| Very low prevalence of vaccine human papillomavirus types among 18-to 35-year old Australian women 9 years following implementation of vaccination DA Machalek, SM Garland, JML Brotherton, D Bateson, K McNamee, ... The Journal of infectious diseases 217 (10), 1590-1600, 2018 | 188 | 2018 |
| A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program D Novakovic, ATL Cheng, Y Zurynski, R Booy, PJ Walker, R Berkowitz, ... The Journal of infectious diseases 217 (2), 208-212, 2018 | 187 | 2018 |
| Anaphylaxis following quadrivalent human papillomavirus vaccination JML Brotherton, MS Gold, AS Kemp, PB McIntyre, MA Burgess, ... CMAJ 179 (6), 525-533, 2008 | 186 | 2008 |
| Safety of human papillomavirus vaccines: an updated review A Phillips, C Patel, A Pillsbury, J Brotherton, K Macartney Drug safety 41, 329-346, 2018 | 165 | 2018 |
| Safety of human papillomavirus vaccines: a review KK Macartney, C Chiu, M Georgousakis, JML Brotherton Drug safety 36, 393-412, 2013 | 162 | 2013 |
| Human papillomavirus vaccine coverage among female Australian adolescents: success of the school‐based approach JML Brotherton, SL Murray, MA Hall, LK Andrewartha, CA Banks, D Meijer, ... Medical Journal of Australia 199 (9), 614-617, 2013 | 159 | 2013 |
| Adolescent and young adult HPV vaccination in Australia: achievements and challenges SM Garland, SR Skinner, JML Brotherton Preventive medicine 53, S29-S35, 2011 | 131 | 2011 |
